In a bid to alleviate the number of COVID-19 cases, China has taken yet another step in approving its fifth COVID-19 vaccine for emergency use in the country. According to reports, this new vaccine stands to be the fifth shot in its arsenal to be given emergency use approval.
It has been reported that the latest vaccine was co-developed by the Chinese Academy of Sciences and Anhui Zhifei Longcom Biopharmaceutical Limited. The teams have already concluded several initial clinical studies in October last year and are currently conducting the third phase trials in Indonesia, Uzbekistan, and Pakistan.
However, the approved vaccines have formerly been limited to adults in the age group of 18 to 59 years, with the Chinese government looking to curb the limits accordingly.
Furthermore, the head of China’s CDC, Gao Fu, has reportedly led the development of a protein subunit vaccine which was granted EUA by the country’s regulators last week.
Reportedly, the apparent COVID-19 vaccine was earlier accepted in Uzbekistan for emergency use on 1st March 2021. It is a 3-dose shot that is given each month. Similar to other vaccines that China has developed so far; the fifth shot is also required to be stored at normal refrigeration temperatures.
Interestingly, China has been relatively slow in vaccinating its 1.4 billion people, despite having four approved vaccines in its spectrum for general use. However, the country is now planning for mass vaccinations, alarmed by the subtle rise in COVID-19 cases.
In fact, Vice-Chairperson of National Health Commission, Li Bin, reportedly cited that the government is looking forward to promptly carrying out mass vaccinations of the populations including health care workers, specific industries, and people who work at the customs or borders.
It was mentioned in a press release that the local health centers in certain neighborhoods in Beijing have also started offering vaccines to people aged 60 and above.
Source Credit –